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ABSTRACT
Neuroblastoma is the most common extracranial solid tumor in childhood. 
Patients in high-risk group often have poor outcomes with low survival rates despite 
several treatment options. This study aimed to identify a genetic signature from 
gene expression profiles that can serve as prognostic indicators of survival time 
in patients of high-risk neuroblastoma, and that could be potential therapeutic 
targets. RNA-seq count data was downloaded from UCSC Xena browser and samples 
grouped into Short Survival (SS) and Long Survival (LS) groups. Differential gene 
expression (DGE) analysis, enrichment analyses, regulatory network analysis 
and machine learning (ML) prediction of survival group were performed. Forty 
differentially expressed genes (DEGs) were identified including genes involved in 
molecular function activities essential for tumor proliferation. DEGs used as features 
for prediction of survival groups included EVX2, NHLH2, PRSS12, POU6F2, HOXD10, 
MAPK15, RTL1, LGR5, CYP17A1, OR10AB1P, MYH14, LRRTM3, GRIN3A, HS3ST5, 
CRYAB and NXPH3. An accuracy score of 82% was obtained by the ML classification 
models. SMIM28 was revealed to possibly have a role in tumor proliferation and 
aggressiveness. Our results indicate that these DEGs can serve as prognostic 
indicators of survival in high-risk neuroblastoma patients and will assist clinicians 
in making better therapeutic and patient management decisions.
INTRODUCTION
Neuroblastoma is the most common extracranial 
solid tumor in childhood accounting for approximately 
15% of pediatric cancer death [1–3]. It develops anywhere 
along the sympathetic nervous system with 60% of the 
tumors occurring in the abdomen, commonly in the 
adrenal gland [4, 5].
Outcomes ranging from spontaneous regression to 
relentless progression despite extensive therapies indicate 
the heterogeneity of neuroblastoma [6]. The Children’s 
Oncology Group (COG) classifies neuroblastoma patients 
into low, intermediate and high-risk groups. Patients 
classified in low-risk groups have good outcomes contrary 
to high-risk groups who present poor outcomes despite 
extensive therapies [4] and with a disproportionate number 
dying or suffering profound treatment related morbidities 
[7, 8]. Tumors in high-risk neuroblastoma patients are 
often metastatic, resulting in survival rates of less than 
50% [1].
Genomic studies associated high-risk neuroblastoma 
with mutations or alterations in a number of genes, such 
as ALK, ATRX and TERT [9–12]. Furthermore, genome 
wide association studies have revealed genetic markers, 
such as CASC15, LMO1, DUSP2 and BARD1 to be 
neuroblastoma susceptibility genes [13–21]. However, 




The objective of our study is to identify a genetic 
signature from gene expression data that can serve 
as prognostic indicators of survival time in high-risk 
neuroblastoma patients and that could be therapeutic 
targets in that patient category.
RESULTS
Querying the Xena TARGET dataset returned 20 
and 12 SS and LS samples, respectively. Based on the gene 
expression levels in these samples, the edgeR filterByExpr 
function removed 35,873 low expressed genes and kept 
24,610 genes for downstream analysis. The DGE analysis 
with DESeq2 identified 40 DEGs between the SS and LS 
groups, of which 21 genes were upregulated and 19 genes 
were downregulated. Table 1 shows information about the 
40 DEGs.
The Gene Ontology (GO) Molecular Function 
enrichment analysis revealed that upregulated genes were 
mainly enriched in MAP kinase activity, retinol binding 
and RNA polymerase II activating transcription factor 
binding, as well as in other activities shown in (Figure 1A). 
No statistically significant results (p-adjusted value < 0.05) 
were obtained for the downregulated genes as well as for 
the other GO categories; Biological Process and Cellular 
Component. In addition, the Disease Ontology enrichment 
analysis associated upregulated and downregulated genes 
with several genetic disorders; intellectual disability, 
cardiac dysfunction, bone development, impaired 
infertility and pulmonary dysfunction caused by 
diaphragm-associated abnormalities (Figure 1B and 1C).
Reconstruction of gene regulatory networks, using 
the GENIE3 algorithm, for the SS and LS samples 
respectively deduced 1,966,606 and 1,967,020 weighted 
interactions involving the DEGs. Applying a weight 
threshold value of 0.00251 resulted in 1018 and 650 
DEG interactions for the SS and LS groups, respectively. 
The visualization of the 1018 DEG interactions using 
Cytoscape enabled the detection of 4 essential regulatory 
networks (Figure 2). The first network (Figure 2A) 
involves SMIM28, LGR5, PRSS12, EVX2, NHLH2 
and HOXD10. All of these DEGs are upregulated, 
and the last three genes are transcription factors. The 
following network (Figure 2B) interconnect MAPK15, 
Lnc-ZNF814-1, EDIL3, NBAS and CYP17A1. The first 
two genes are upregulated and the last three genes are 
downregulated. Most of the DEGs in the third and last 
networks (Figure 2C and 2D) are downregulated with the 
exception of MEG9 and STRA6 which are upregulated. 
Interestingly, these interactions between the DEGs are 
Figure 1: Gene and disease enrichment analyses. Molecular Function activities enriched by the upregulated DEGs (A). Network 
representations of enriched diseases for upregulated DEGs (B) and downregulated DEGs (C) (absolute value of fold change > 1.5). The 
size of the circles represents the number of genes that enrich a disease.
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Table 1: Upregulated and downregulated DEGs in SS neuroblastoma samples compared to LS 
samples
Symbol Name log2FC p-adj Status
SMIM28 small integral membrane protein 28 5.4652 0.0146 Up
EVX2 even-skipped homeobox 2 4.9304 0.0014 Up
NHLH2 nescient helix-loop-helix 2 4.2404 0.0046 Up
PRSS12 serine protease 12 3.4788 0.0168 Up
POU6F2 POU class 6 homeobox 2 3.4534 0.0430 Up
HOXD10 homeobox D10 3.3386 0.0357 Up
MAPK15 mitogen-activated protein kinase 15 3.0939 0.0499 Up
RTL1 retrotransposon Gag like 1 2.8233 0.0241 Up
LGR5 leucine rich repeat containing G protein-coupled receptor 5 2.7453 0.0386 Up
DPY19L2P4 DPY19L2 pseudogene 4 2.6439 0.0187 Up
STRA6 signaling receptor and transporter of retinol STRA6 2.5625 0.0437 Up
MEG9 maternally expressed 9 1.9449 0.0146 Up
LINC01410 long intergenic non-protein coding RNA 1410 1.6411 0.0334 Up
CYP17A1 cytochrome P450 family 17 subfamily A member 1 4.1951 0.0005 Down
OR10AB1P olfactory receptor family 10 subfamily AB member 1 pseudogene 4.0068 0.0146 Down
MYH14 myosin heavy chain 14 3.7783 0.0317 Down
LRRTM3 leucine rich repeat transmembrane neuronal 3 3.6646 0.0168 Down
GRIN3A glutamate ionotropic receptor NMDA type subunit 3A −3.1104 0.0445 Down
HS3ST5 heparan sulfate-glucosamine 3-sulfotransferase 5 −2.9968 0.0168 Down
NBAS NBAS subunit of NRZ tethering complex −2.8992 0.0146 Down
FNDC9 fibronectin type III domain containing 9 −2.8611 0.0419 Down
H1-4 H1.4 linker histone, cluster member −2.8427 0.0146 Down
CRYAB crystallin alpha B −2.7802 0.0146 Down
NXPH3 neurexophilin 3 −2.5502 0.0348 Down
MYL3 myosin light chain 3 −2.5310 0.0437 Down
CMYA5 cardiomyopathy associated 5 −2.4531 0.0311 Down
AMIGO2 adhesion molecule with Ig like domain 2 −2.2807 0.0499 Down
SIK1B salt inducible kinase 1B (putative) −2.2002 0.0446 Down
EDIL3 EGF like repeats and discoidin domains 3 −2.1682 0.0311 Down
UBC ubiquitin C −1.1926 0.0499 Down
lnc-FANCC-1 2.6996 0.0437 Up
lnc-KLHL28-1 2.5450 0.0311 Up
lnc-TBCCD1-4 2.1511 0.0051 Up
lnc-CDC27-8 2.1123 0.0146 Up
lnc-SPG21-45 2.0232 0.0166 Up
AC137695.1 2.0062 0.0146 Up
Lnc-NSUN6-1 1.5671 0.0499 Up
Lnc-ZNF814-1 1.3445 0.0146 Up
Lnc-METRNL-8 −2.8955 0.0311 Down
Lnc-METRNL-1 −2.5951 0.0437 Down
Shown are gene symbols, gene names, fold change (log2FC), p-adjusted value and gene expression status. Genes without 
names are non coding RNAs (LNCipedia GeneIDs) except AC137695.1.
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not present in the LS group and the following genes; 
SMIM28, HOXD10, PRSS12, NHLH2, MEG9, MAPK15, 
Lnc-ZNF814-1 and FNDC9, have no interactivity with 
any other DEG (Supplementary Text 1: SS-DEG-Net.tsv 
and LS-DEG-Net.tsv respectively store the 1018 and 650 
interactions that can be viewed with Cytoscape).
Filtering the GSE49711 dataset with the query 
criteria of Table 3 yielded 43 SS and 19 LS samples, 
respectively. DEGs that do not have an associated NCBI 
GeneID were not found in this dataset, particularly those 
that are identified as long non-coding RNAs (lncRNAs). 
Only 25 of the 40 DEGs have expression data in this 
dataset. Based on the results of feature selection with 
scikit-learn and several classification tests, the following 
16 features were selected for the machine learning 
construction of the training and test sets; EVX2, NHLH2, 
PRSS12, POU6F2, HOXD10, MAPK15, RTL1, LGR5, 
CYP17A1, OR10AB1P, MYH14, LRRTM3, GRIN3A, 
HS3ST5, CRYAB and NXPH3. The evaluation of the 
Support Vector Machines (SVM) and Artificial Neural 
Networks (ANN) models using 5-fold cross-validation 
resulted in an accuracy of 78% and 87% for SVM and 
ANN, respectively. By testing the ML models on the 
GSE49711 test set, ANN again achieved better results with 
an accuracy of 82% of samples correctly classified as SS 
or LS compared to SVM which obtained an accuracy of 
79% (Table 2).
DISCUSSION
We aimed at identifying genes that are differentially 
expressed between high-risk SS and LS patients that 
could be potential prognostic indicators and or therapeutic 
targets. The results of the DGE analysis between the two 
groups showed the upregulation and downregulation of 
genes associated with neuroblastoma and other cancers.
Differentially expressed genes
Upregulated genes
The upregulated DEGs included some genes whose 
overexpression in the SS group have been correlated with 
poor survival in neuroblastoma and other cancers. Higher 
expression levels of NHLH2 were found to be higher 
in unfavourable neuroblastomas and was significantly 
associated with a poor prognosis [22]. Additional roles 
of NHLH2 in the obesity and fertility has also been 
uncovered [23, 24]. The upregulation of PRSS12 in this 
study is similar to the results of Hiyama et al. [25], which 
reported the overexpression of PRSS12 in neuroblastoma 
tumors with high telomerase activity correlating with 
unfavourable tumors. Serine proteases are often altered 
and significantly upregulated in cancer as malignant cells 
need proteolytic activities to enable their growth, survival 
Figure 2: (A–D) Gene Regulatory Network Analysis. Regulatory networks for the DEG interactions in the SS group. The brown hexagonal 
nodes are DEGs and the blue rectangles are intermediate genes connecting two DEGs. DEGs that do not interact with other DEGs are 
omitted.
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and expansion. Our result support that upregulation of 
PRSS12 is indicative of poor survival in neuroblastoma. 
HOXD10 is a transcription factor whose expression is 
altered in many cancers. Its high expression gives cancer 
cells proliferative and migratory abilities [26]. Elevated 
expression of HOXD genes including HOXD10 was 
reported to be associated with unfavourable prognosis 
and poor outcome in neuroblastoma [27], which supports 
our results indicating a more aggressive disease in the 
SS group. LGR5 is a stem cell marker which is highly 
expressed and associated with an aggressive phenotype in 
neuroblastoma [28, 29]. It has also been associated with 
pancreatic ductal adenocarcinoma [30] and colorectal 
cancer [31]. LGR5 potentially contributes to stem cell 
maintenance and self renewal and is indicative of poor 
survival in high-risk neuroblastoma. SMIM28 is a less 
studied protein whose upregulation is indicative of poor 
survival in this study. Similar to our results, Jiang et al. 
[32] reported the upregulation of SMIM28 in prostate 
cancer. EVX2 is a homeobox transcription factor essential 
for vertebrate spinal cord neuronal specification [33]. 
POU6F2 belongs to the POU class homeobox family 
whose members are transcriptional regulators and is 
involved in hereditary predisposition to Wilms tumor, 
a pediatric malignancy of the kidney [34]. Functional 
studies are required to elucidate the roles of SMIM28, 
EVX2 and POU6F2 in high-risk neuroblastoma.
MAPK15, a protein kinase involved in many cellular 
activity including cell proliferation was upregulated 
in this study. Highest levels of MAPK15 was found in 
aggressive embryonal carcinomas and it acts by sustaining 
the progression of the cell cycle of embryonal carcinomas 
by limiting p53 activation and preventing the facilitation 
of p53 dependent mechanisms that results to the arrest 
of the cell cycle [35]. Neuroblastoma is a malignancy of 
embryonal origin and upregulation of MAPK15 would 
be expected to facilitate tumor progression and indicative 
of aggressive disease and poor survival as in the SS 
group. RTL1, a paternally expressed imprinted gene 
highly expressed in the fetus, placenta and brain. It has 
been reported to be a driver of hepatocellular carcinoma 
[36]. Being a protease, it possibly promotes tumor 
invasion and metastasis in neuroblastoma tumors. Higher 
expression of RTL1 is thus suggestive of poor prognosis 
in neuroblastoma. Also upregulated is STRA6, a plasma 
membrane protein that transports retinol and is involved 
in a signalling mediated by JAK2, STAT3 and STAT5 
[37]. Its upregulation indicates poor survival in our study 
possibly through its maintenance of cancer stem cells and 
promotion of tumor formation as reported in colorectal 
cancer [37, 38].
Ten lncRNAs were upregulated in this study. 
Three of these (lnc-SPG21-45, lnc-NSUN6-1 and lnc-
KLHL28-1) are antisense to ANKDD1A, CACNB2 
and C14orf28 genes, respectively, which are associated 
with other cancers and diseases, possibly by regulating 
their expression. C14orf28 has been observed to be 
overexpressed in colorectal cancer cells, promoting 
proliferation, migration and invasion [39]. ANKDD1A 
has been described as a functional tumor suppressor 
with germline variants predicting poor patient outcomes 
in low grade glioma [40], and is frequently methylated 
in glioblastoma multiforme [41] and in clinically non-
functioning pituitary adenomas [42]. CACNB2 is a 
calcium channel protein linked to diabetic retinopathy 
[43], bipolar disorder [44], hypertension [45] and autism 
spectrum disorders [46]. The role of calcium signalling in 
cancer has been reviewed by [47–49]. MEG9, is located 
in an imprinted non-coding RNA genomic region, DLK1-
DIO3 [50, 51]. LINC01410 is a lncRNA highly expressed 
in pancreatic cancer tissues and cell lines [52]. High 
expression in cholangiocarcinoma and gastric cancer 
patients have been associated with poor prognosis and 
survival [53, 54]. These lncRNAs may be facilitating 
the promotion of tumor progression, proliferation and 
invasion which might have impacted the survival of 
patients in the short survival group. It is well established 
that metastasis is the primary cause of cancer mortality. 
Functional studies are required to evaluate the roles of 
these lncRNAs in neuroblastoma.
Downregulated genes
The downregulated genes include genes such as 
AMIGO2, LRRTM3, GRIN3A, MYH14, EDIL3, FNDC9, 
involved in neural function and development, and in 
extracellular matrix (ECM) organization. AMIGO2 is a 
transmembrane molecule expressed in neuronal tissues and 
participates in their formation [55]. EDIL3 is an inducer 
of the epithelial-mesenchymal transition, that promotes 
angiogenesis and invasion in hepatocellular carcinoma 
[56]. FNDC9 which exhibits biased expressed in the brain 
is an ECM protein involved in tumorigenesis in different 
cancers [57]. MYH14 is a myosin, an actin-dependent 
motor protein that plays a role in neuritogenesis. Members 
Table 2: Machine learning results for the classification of the GSE49711 test set of high-risk 
neuroblastoma samples with SVM and ANN models
SVM ANN
Class Precision Recall Precision Recall
Short Survival 0.87 0.81 0.86 0.88
Long Survival 0.64 0.74 0.72 0.68
Accuracy 79% 82%
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of the myosin superfamily have been known to enhance 
or suppress tumor progression [58]. MYH14 could be 
suppressing tumor progression in high-risk neuroblastoma. 
The downregulation of these ECM associated genes 
could be promoting the invasion and metastasis of 
neuroblastoma tumors.
OR10AB1P belongs to the olfactory receptor family 
of genes. Olfactory receptors are expressed in various 
human tissues and are involved in different cellular 
processes such as migration and proliferation. Some 
are biomarkers for prostate, lung and small intestine 
carcinoma tissues [59]. Decreased expression of CRYAB 
indicated its tumor suppressor function in bladder cancer 
[60]. It may thus also be functioning as a tumor suppressor 
in neuroblastoma. Ubiquitin C (UBC) is a polyubiquitin 
precursor. Ubiquitination has been associated with many 
cellular processes which play roles in tumorigenesis.
CYP17A1 is a key enzyme in the steroidogenic 
pathway with restricted expression in the adrenal gland. 
Neuroblastoma tumors commonly occur in the adrenal 
medulla. The downregulation of CYP17A1 may be an 
indicator of poor prognosis in neuroblastoma. LRRTM3 
has high expression in the brain and belongs to a group of 
proteins involved in nervous system development. How it 
contributes to neuroblastoma remains to be investigated 
but it is currently a candidate gene for alzheimer’s disease 
[61, 62], a neurological disorder. NBAS is thought to 
be involved in golgi-to-ER transport and is typically 
amplified in MYCN-amplified neuroblastoma tumors 
[63]. GRIN3A is a glutamate receptor that promotes 
nerve outgrowth [64]. The downregulation of GRIN3A 
may suggest a higher level of disease because glutamate 
is a major excitatory neurotransmitter in the CNS that is 
involved in many neuronal processes. Functional studies 
are required to investigate how these genes contribute to 
poor survival in neuroblastoma.
Gene and disease ontology enrichment analyses
The molecular function activities; MAP kinase 
activity, retinol binding and RNA polymerase II activating 
transcription factor binding, enriched by the upregulated 
genes MAPK15, STRA16 and NHLH2, respectively, 
are activities that promote tumor cell proliferation. 
Deregulation of the MAPK signalling was associated with 
cancer development, progression and cell proliferation 
[65, 66]. Retinol binding through the STRA6 upregulation 
activates a signalling cascade that is found to play a 
role in cancer initiation, maintenance and growth [38]. 
Furthermore, the increased global transcription activity 
(activation of RNA polymerase II) indicates an intensity of 
a rapid proliferation of cancer cells [67]. These activities 
again demonstrate the aggressiveness of the neuroblastoma 
tumors in SS patients compared to LS patients.
The enriched diseases by the upregulated and 
downregulated genes, particularly the disorders 
inducing heart failure (Cardiomyopathy and Congenital 
heart disease) and respiratory illness (Diaphragmatic 
dysfunction) may have negative impact on survival 
[68, 69], and could be the cause of death in the SS 
neuroblastoma patients. There is no indication in the 
clinical information accompanying the gene expression 
count dataset if the patients suffered from additional 
disorders in addition to neuroblastoma. However, it is 
reported that high-risk neuroblastoma survivors treated 
with intensive multimodality therapy are at risk for a broad 
variety of treatment-related late effects including cardiac 
dysfunction, bone development disease, pulmonary 
dysfunction and impaired fertility [70]. These treatment-
related morbidities were enriched by the upregulated and 
downregulated DEGs (Figure 1B and 1C), suggesting that 
the cause of death in patients with SS neuroblastoma may 
be due to treatment complications.
Regulatory network analysis
After the application of a weight threshold of 0.00251 
to the GENIE3 output, the numbers of interactions involving 
the DEGs in the SS and LS groups were 1018 and 650, 
respectively. There is a clear substantial difference in number 
of interactions between the two groups, indicating a higher 
cellular/tumor activity in the SS group which could be a sign 
of tumor aggressiveness in patients with SS neuroblastoma. 
In addition, it is noticeable from the networks in Figure 2 the 
importance of the genes SMIM28, MAPK15 and UBC as 
origins of most of the interactions. The role of MAPK15 and 
UBC in tumorigenesis has been reported in many previously 
discussed scientific works, while SMIM28 is a less studied 
gene with an unclear role in cancer. However, observation 
of the role of the final target genes of SMIM28 in Figure 
2A network, which are LGR5 and HOXD10, can shed light 
on the role of this gene. As reported previously, both LGR5 
and HOXD10 were associated with cancer cell proliferation 
and tumor aggressiveness in neuroblastoma. Thus, it is 
Table 3: Query criteria for short survival (SS) and long survival (LS) sample selection
Field SS values LS values
Diagnostic category Neuroblastoma Neuroblastoma
INSS stage Stage 4 Stage 4
COG risk group High risk High risk
Vital status Dead Alive
Overall survival time 730 days 2555 days
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possible that SMIM28 (Small Integral Membrane Protein 
28) is part of a signalling pathway whose role is to accelerate 
neuroblastoma tumor proliferation, making it a possible 
new gene target therapy in high-risk neuroblastoma cancer. 
Further investigations are required to elucidate precisely the 
role of SMIM28 in the aggressiveness of neuroblastoma 
tumors.
Machine learning
Although not all the DEGs were included in the 
training and testing of the machine learning models, the 
obtained prediction results were significantly good. The 
ANN model obtained the highest accuracy of 82% for 
the classification of the external neuroblastoma samples 
(GSE49711) into short and long survival classes. This 
high classification accuracy makes it possible to consider 
that the DEG expression profiles have been preserved 
in the various high-risk neuroblastoma tumors, although 
neuroblastoma is known to be heterogeneous. Therefore, 
the DEG list can serve as prognostic indicators (genetic 
signature) for survival time in high-risk neuroblastoma 
patients and can be targets for drug discovery analyses. 
Relatively similar to our study, other studies have 
proposed genetic signatures for prognostic stratification 
of patients with neuroblastoma. Liu et al. [71] used an 
unsupervised biclustering machine learning technique to 
find high-risk neuroblastoma subtypes. They proposed a 
signature of 238 neuroblastoma-specific immune genes 
to identify ultra high-risk and high-risk neuroblastoma 
subtypes. Russo et al. [72] applied K-means clustering 
to 27 kinome gene signature to identify ultra high-risk 
subtypes of high-risk neuroblastoma. Formicola et al. [73] 
used Cox regression and Kaplan-Meier analysis methods 
to propose a 18-gene expression based risk scoring 
system to predict overall survival of patients with stage 
4 neuroblastoma. We demonstrated the use of a shorter 
signature in a 16-gene expression classifier based on 
survival time to stratify high-risk neuroblastomas into SS 
(ultra high-risk) and LS subtypes. The number of genes in 
our classifier should provide the advantage of being less 
costly and easier to implement.
Figure 3: Workflow outlining the steps and methods undertaken in this study.
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MATERIALS AND METHODS
The workflow describing the steps and methods 
undertaken in this study is illustrated in Figure 3. It 
includes 5 essential steps; dataset retrieval, differential 
gene expression, disease/gene ontology enrichment, gene 
regulatory network inference and machine learning.
Datasets
The Therapeutically Applicable Research to 
Generate Effective Treatments (TARGET) initiative 
employed comprehensive molecular characterization 
of hard-to-treat childhood cancers which included 
neuroblastoma. TARGET data is accessible via the 
TARGET data matrix as well as via the Xena browser. The 
Xena browser is a web based visualization and exploration 
tool for multi-omic data large public repositories and 
private datasets [74]. The TARGET neuroblastoma 
dataset in the Xena database [74, 75] is composed of 
high-risk neuroblastoma samples with available clinical 
information. Gene expression RNA-seq read counts of the 
TARGET neuroblastoma dataset (dataset ID: TARGET-
NBL. htseq_counts. tsv) were obtained from the GDC hub 
in Xena browser using xenaPython package. Fields used in 
querying the dataset are described in Table 3. The dataset 
itself was composed of 151 samples in total. Querying the 
dataset with the above fields returned 32 neuroblastoma 
samples; 20 of which with an overall survival time of less 
than 730 days (2 years) and vital status is “dead” were 
considered short survival (SS), while 12 samples with an 
overall survival time greater than 2555 days (7 years) and 
vital status is “alive” were considered long survival (LS).
Differential gene expression analysis
Normalized expression counts were converted to 
raw counts and filtered to remove low expressed genes 
using the edgeR filterByExpr function in R [76]. We 
then performed a differential gene expression (DGE) 
analysis between the short and long survival groups 
using the DESeq2 package in R [77]. DESeq2 uses 
shrinkage estimators for dispersion and fold change for 
its comparative differential gene expression estimation 
[77]. Differentially expressed genes (DEGs) were selected 
by meeting criteria of adjusted p-value < 0.05. Gene 
Ontology (GO) enrichment analysis was carried out to 
functionally annotate the DEGs using clusterProfiler [78] 
and visualized using enrichplot. The DOSE R library [79] 
was used to detect the diseases enriched by the upregulated 
and downregulated DEGs.
Machine learning
Scikit-learn [80] and LibSVM [81] libraries were 
used for machine learning (ML) model creation and 
classification tasks. Features (genes) not present in the test 
dataset (GSE49711) were not used for machine learning 
prediction. The top upregulated and downregulated genes 
used as features for machine learning (ML) prediction of 
patient survival were; EVX2, NHLH2, PRSS12, POU6F2, 
HOXD10, MAPK15, RTL1, LGR5, CYP17A1, OR10AB1P, 
MYH14, LRRTM3, GRIN3A, HS3ST5, CRYAB, NXPH3. 
The features were extracted from the log-normalized 
counts data. For LibSVM, the feature values of the training 
and test sets were scaled using a built-in python script. 
With regards to ANN, the feature values of the training and 
test sets were scaled with the Scikit-learn MinMaxScaler 
function. Algorithms used for training and evaluation of 
the models include; Support Vector Machines (SVM) 
and Artificial Neural Networks (ANN). 5-fold cross 
validation was done to determine the best parameters 
of the SVM and ANN models which was then applied 
to our test samples. Both models, created with LibSVM 
and ANN were applied to predict the classification of 
samples in an external dataset (GSE49711) with same 
sample characteristics (overall survival < 730 days with 
vital status as dead for SS samples, and overall survival > 
2555 days with vital status as alive for LS samples). The 
evaluation metrics for the LibSVM and ANN models were 
precision, recall and accuracy.
Regulatory networks
The GENIE3 package [82] in R was used for genetic 
regulatory network inference analysis. The GENIE3 
algorithm uses a Random Forest or Extra Randomized 
Trees approach to infer gene regulatory networks from 
gene expression data [82]. It outputs a ranked list of each 
pairwise comparison from the most to the least confident 
regulatory connection. The library was run on the gene 
expression counts from the SS and LS samples separately. 
For the output analysis, only connections involving the 
DEGs were considered. In addition, a weighting threshold 
of 0.00251 was applied to reduce the large number of 
connections and also to focus on high confident regulatory 
connections. Cytoscape [83] was used for the visualization 
of gene regulatory networks. 
CONCLUSIONS
The DGE analysis is a powerful technique for 
identifying DEGs in a studied condition. In this study, 
using DESeq2 we identified 40 DEGs between SS and LS 
neuroblastoma samples. Many of the DEGs were found to 
be related to different cancers (including neuroblastoma), 
thus strengthening their possibility of being associated 
with neuroblastoma. The ML models based on 16 DEGs 
were capable of stratifying high-risk neuroblastoma 
samples on the basis of survival time, demonstrating their 
ability to be used as a genetic signature or prognostic 
indicators of survival in high-risk neuroblastoma 
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patients. This study furthers our understanding of the 
molecular mechanisms of neuroblastoma in high-risk 
patients. We identified SMIM28 gene to be critical for 
tumor proliferation making it as a possible gene therapy 
target. Nevertheless, additional studies are required to 
elucidate the role of SMIM28 in the pathogenesis of 
neuroblastoma. Finally, prognostic stratification of high-
risk neuroblastoma patients will help clinicians in making 
better therapeutic and patient management decisions.
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